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http://dx.doi.org/10.1016/j.jfma.201Pneumothorax is defined as the presence of air in the pleural cavity. Spontaneous pneumo-
thorax, occurring without antecedent traumatic or iatrogenic cause, is sub-divided into pri-
mary and secondary. The severity of pneumothorax could be varied from asymptomatic to
hemodynamically compromised. Optimal management of this benign disease has been a mat-
ter of debate. In addition to evacuating air from the pleural space by simple aspiration or chest
tube drainage, the management of spontaneous pneumothorax also focused on ceasing air
leakage and preventing recurrences by surgical intervention or chemical pleurodesis. Chemical
pleurodesis is a procedure to achieve symphysis between the two layers of pleura by sclerosing
agents. In the current practice guidelines, chemical pleurodesis is reserved for patients unable
or unwilling to receive surgery. Recent researches have found that chemical pleurodesis is also
safe and effective in preventing pneumothorax recurrence in patients with the first episode of
spontaneous pneumothorax or after thoracoscopic surgery and treating persistent air leakage
after thoracoscopic surgery. In this article we aimed at exploring the role of chemical pleurod-
esis for spontaneous pneumothorax, including ceasing air leakage and preventing recurrence.
The indications, choice of sclerosants, safety, effects, and possible side effects or complica-
tions of chemical pleurodesis are also reviewed here.
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3.10.016Definition and classification of spontaneous
pneumothorax
Pneumothorax, a common pleural disease worldwide, is
defined as the presence of air in the pleural cavity, resulting
in parenchymal collapse.1 Pneumothorax can impair
oxygenation and/or ventilation. If the pneumothorax is& Formosan Medical Association. All rights reserved.
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compromise hemodynamic stability. Clinically, pneumo-
thorax is divided into spontaneous and traumatic. Sponta-
neous pneumothorax is sub-divided into primary and
secondary, according to with or without precipitating un-
derlying lung disease.24
Primary spontaneous pneumothorax (PSP), which is
defined as a pneumothorax without obvious underlying lung
disease, most commonly occurs in young, tall, lean
males.2,4 PSP occurs at a frequency of 7.4e18 cases per
100,000 population per year in men and in 1.2e6 cases per
100,000 population per year in women.5,6 With regard to
the etiology of PSP, anatomical abnormalities are
commonly demonstrated at the apex of the lung.
Emphysema-like changes, including subpleural blebs and
bullae were found in 50e90% of PSP patients on high-
resolution computed tomography (CT) scanning and in
76e100% of PSP patients during video-assisted thoraco-
scopic surgery (VATS) or thoracotomy.712
Secondary spontaneous pneumothorax (SSP) usually oc-
curs in older people with underlying lung disease, such as
emphysema, chronic obstructive lung disease, catamenial
pneumothorax, cystic fibrosis, pulmonary infection, or
lymphangioleiomyomatosis.3,13e16Clinical presentation and diagnosis of
spontaneous pneumothorax
Sudden onset of dyspnea and pleuritic chest pain were most
complained.17,18 The severity of the symptoms is primarily
related to the volume of air in the pleural space. Symptoms
are greater in SSP, even if the pneumothorax is relatively
small in size.4 Owing to the additional presence of the pa-
tient’s underlying lung disease, SSP is considered a poten-
tially life-threatening event, whereas PSP is virtually
always a nuisance rather than a life-threatening
condition.19
Diagnosis of pneumothorax is confirmed by imaging
studies, primarily a plain chest film obtained during forced
inspiration with the patient in a standing position.20,21 The
presence of a pneumothorax is established by demon-
strating a white visceral pleural line on the chest radio-
graph. Inspiratory and expiratory films have equal
sensitivity in detecting pneumothoraces; thus, a standard
inspiratory chest radiograph is sufficient in most cases.
The percentage of collapsed lung can be estimated using
a plain chest film by the measurement of the average
diameter of the collapsed lung and the involved hemithorax
(Light’s formula).22
Although chest CT scans can reveal the underlying
pathophysiologic lesions that cause spontaneous pneumo-
thorax and can be regarded as the “gold standard” in the
detection of small pneumothoraces and in size estima-
tion,23,24 the American Collage of Chest Physicians (ACCP)
does not recommend the routine use of this imaging tech-
nique for patients with first-time primary or secondary
pneumothoraces.21 CT may, however, be useful for evalu-
ating patients with recurrent secondary pneumothorax, to
determine the best treatment for persistent air leakage, or
to plan a surgical intervention.25 The British Thoracic So-
ciety (BTS) recommends using CT when required todifferentiate between pneumothorax and bullous lung dis-
ease, when aberrant tube placement is suspected and when
the plain chest radiograph is difficult to read owing to the
presence of subcutaneous emphysema.4Treatment options for spontaneous
pneumothorax
The management of pneumothorax focused on evacuating
air from the pleural space, ceasing air leakage, and pre-
venting recurrences.4,19,21 Available therapeutic options
include observation, simple aspiration, intercostal drainage
with a pigtail catheter or chest tube, intercostal drainage
with chemical pleurodesis, medical thoracoscopy with
chemical pleurodesis, or surgical intervention (VATS or
thoracotomy) with/without chemical pleurodesis. The se-
lection of an approach depends on the size of the pneu-
mothorax, the severity of symptoms, whether there is a
persistent air leakage, and whether the pneumothorax is
primary or secondary.4,19,21 Generally, surgical intervention
is reserved for patients with recurrent or complicated
spontaneous pneumothorax, and chemical pleurodesis can
be used as an adjunct after drainage or surgery.Chemical pleurodesis
Pleurodesis is a procedure to achieve symphysis between
the two layers of pleura to prevent recurrent pleural
effusion or recurrent pneumothorax.4,26,27 Either instilling a
chemical irritant (chemical pleurodesis) or performing
mechanical abrasion (mechanical pleurodesis) that induced
inflammation and fibrosis caused the symphysis between
the two layers of pleura.8 Clinically, chemical pleurodesis
was widely applied for stopping air-leak or for preventing
pneumothorax recurrence. Chemical pleurodesis can be
applied through the intercostal drainage tube, medical
thoracoscopy, or during the operation. In clinical practice,
a variety of sclerosants have been used, including tetra-
cycline and derivatives (doxycycline or minocycline), talc,
bleomycin, autologous blood patch, iodopovidone, piciba-
nil, silver nitrate, and quinacrine.2731 In a survey from five
English-speaking countries (United States, United Kingdom,
Canada, Australia, and New Zealand), the most commonly
used agent was talc followed by tetracycline derivatives
and bleomycin.32Chemical pleurodesis for persistent air leakage
after chest drainage
Persistent air leakage is defined as air leakage more than
5e7 days after intercostal drainage, which are more com-
mon with secondary pneumothorax than with primary
pneumothorax.3335 For patients with persistent air
leakage, physicians must consider surgical intervention to
prevent prolonged hospitalization and the possibility of a
recurrent pneumothorax.4,19,21 VATS has been advocated in
the management of patients with PSP and the selection of
patients with SSP who suffer from persistent air
leakage.33,3639 For patient has objective evidence of
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option.
In 1994, Alfageme et al40 reported that the intrapleural
instillation of tetracycline has 60% of success rate among
spontaneous pneumothorax patients with persistent air
leakage. Cagirici et al41 in 1998 conducted a prospective
randomized study to examine the efficacy of autologous
blood patch pleurodesis when compared with tube thor-
acostomy alone. Air leakage resolution occurred in 84% of
patients within 72 hours and was significantly reduced when
compared with tube thoracostomy alone.Chemical pleurodesis for preventing
pneumothorax recurrence
One of the most important issues of managing spontaneous
pneumothorax is to prevent pneumothorax recurrence. The
1-year recurrence rate in PSP patients with the first episode
using chest tube drainage is around 30% (16e52%) and pro-
gressively increases after the second or third episode.19,42
Although chemical pleurodesis effectively reduces the
recurrence of spontaneous pneumothorax in surgical and
nonsurgical patients,22,4345 published guidelines do not
recommend it as the initial treatment for primary sponta-
neous pneumothorax.4,1921
In a recent published clinical trial, Chen et al46 ran-
domized patients with the first episode of PSP to simple
aspiration/drainage only (control, n Z 108) or simple
aspiration/drainage and minocycline pleurodesis (nZ 106).
After a follow-up for at least 12 months, pneumothorax
recurrence was lower in the minocycline group (29.2%)
compared with controls (49.1%), which led to fewer sub-
sequent surgical interventions.46 Autologous blood patch
pleurodesis maybe also effective to prevent pneumothorax
recurrence. The pneumothorax recurrence rate following
autologous blood patch pleurodesis ranged from 0% to 29%,
in comparison with tube thoracostomy alone 35e41%.4749
Although surgical treatment is the most effective way in
treating spontaneous pneumothorax, 5e15% of patients
developed pneumothorax recurrence after thoracoscopic
surgery, which is significantly higher compared with thora-
cotomy (0e1%).4,44,50,51 The possible explanations have
included inadequate exposure of chest cavity and
decreased severity of pleural inflammation caused by
thoracoscopy than by thoracotomy.36,44 Loubani et al52 re-
ported significant reduced rates of pneumothorax recur-
rence in patients who underwent thoracoscopic staple
bullectomy alone (20%) against those who received bul-
lectomy and tetracycline pleurodesis (4%). Similar result
was also reported by Chen et al43,44 that additional mino-
cycline pleurodesis after thoracoscopic surgery had lower
pneumothorax recurrence compared with thoracoscopic
surgery alone.Chemical pleurodesis for postoperative air
leakage after surgery for pneumothorax
Prolonged air leakage is the most common complication,
range from 7% to 14%, following thoracoscopic treatment
for PSP, and the optimal management is rarelymentioned.35,5355 Recently, How et al55 reported that
chemical pleurodesis using OK-432 or minocycline were
effective to cease air leakage for patients of PSP with
prolonged air leakage after thoracoscopic surgery.
Furthermore, patients undergoing OK-432 pleurodesis
seems to be more effective by having shorter durations of
post pleurodesis chest drainage and postoperative hospital
stay than those undergoing minocycline pleurodesis.55
Sclerosing agents for chemical pleurodesis
Talc
At the present time, talc is one of the agents most
commonly used for chemical pleurodesis in patients with
either a spontaneous pneumothorax or a recurrent pleural
effusion, even though the occasional reports of severe side
effects.32,56 There are at least 32 cases of adult respiratory
failure syndrome (ARDS) following intrapleural talc admin-
istration in the literature, 17 following the use of talc
slurry, and the remaining 15 following talc insufflation.56e58
The development of ARDS after talc pleurodesis was
later found to be related to the size of the particles as well
as the employed doses. In a multicentre prospective study
conducted by Bridevaux et al,59 including 418 patients
diagnosed with spontaneous pneumothorax, neither ARDS
nor pneumonitis cases were reported using low doses of talc
(2 g) and medium-sized particles (31.5 mm).
Empyema is also reported after talc pleurodesis, which
may be related to techniques used for the sterilization of
talc.60,61 The other concern regarding the potential effect
of long-term pulmonary function by talc pleurodesis on
young pneumothorax patients has been addressed.
Although Lange et al28 showed only a mild restrictive res-
piratory impairment at a follow-up of 22e35 years, Dubois
et al53 showed that thoracoscopic apical bullectomy and
talc poudrage would cause changes in pulmonary function
at 1 year.
Another important concern in patients undergoing talc
pleurodesis is the possibility of false positives in the inter-
pretation of fluorine 18 (18 F) flurorodeoxyglucose (FDG) due
to a high capitation of FDG in the acute and chronic phases of
pleural inflammation, leading to pleural symphysis or the
appearance of pleural pseudotumoral granulomatous (tal-
coma) or pseudosarcomatous reactions, similar to primary
malignant tumoral or metastatic lesions with increased
metabolic activity as reported by the positron emission
tomography-computed tomography (PET-CT).62
Tetracycline and minocycline
Tetracycline, which was the most commonly used irritant,22
is no longer available. Minocycline, a derivative of tetra-
cycline, is as effective as tetracycline in inducing pleural
fibrosis in rabbits.63 No major complication or mortality was
associated with chemical pleurodesis using minocycline.
The main disadvantage of minocycline is immediate chest
pain after instillation, which is relieved spontaneously
within several hours and does not impair pulmonary func-
tion or increase the risk of residual chest pain 6 months
after the operation.43,44
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Bleomycin was widely used for the treatment of malignant
pleural effusions because of its antineoplastic actions and
because it appeared comparable in effectiveness to tetra-
cycline in the treatment of malignant pleural effusions.64,65
In an animal study, Vargas et al64 revealed that the intra-
pleural injection of bleomycin was ineffective in creating
pleural fibrosis, either grossly or microscopically. As bleo-
mycin is expensive and relatively ineffective compared
with other sclerosing agents,31 it is not recommended be
used as a pleural sclerosant in patients with non-neoplastic
pleural disease, such as pneumothorax, congestive heart
failure, or liver cirrhosis.64Autologous blood patch
In contrast to other chemical irritants for pleurodesis such
as talc or tetracycline, autologous blood patch does not
cause systemic inflammatory reactions or severe pain. The
procedure of pleurodesis with autologous blood was as
following: 50 mL of autologous blood without anticoagulant
was obtained from each patient. As soon as the blood was
drawn, it was immediately injected into the pleural space
through a chest tube.66 Although transient fever may
develop following autologous blood patch pleurodesis,48,67Table 1 Indications, effects, and complications of chemical pl
Sclerosing agent Indications Effe
Talc28,30,45,53,58e61,74,75 Initial treatment for PSP
and SSP
Dec
rec
Autologous blood
patch29,34,41,47e49,66e68
Initial treatment for PSP
and SSP
Cea
75e
Dec
rec
afte
Tetracycline22,27,40,76 Initial treatment for PSP
and SSP
Dec
rec
Minocycline55 Prolonged air leakage for
PSP after VATS
Cea
Minocycline11,46 Initial treatment for PSP Dec
rec
Minocycline43,44,77 Adjuvant treatment for
PSP after VATS
Dec
rec
Povidone-iodine30,72,73 Initial treatment for PSP
and SSP
Dec
rec
Picibanil55,69 Adjuvant treatment for
PSP after VATS
and initial treatment for
SSP
Cea
and
pne
to 5
ARDSZ acute respiratory distress syndrome; PSPZ primary spontane
VATS Z video-assisted thoracoscopic surgery.most authors emphasized that no major complication was
observed.49 Other possible complications of autologous
blood patch pleurodesis have included empyema and
pleural effusions.41 However, a reported case of tension
pneumothorax highlights the potential risk for an
obstructing clot in the chest tube.68
OK-432 (Picibanil)
OK-432 (Picibanil ), a lyophilized mixture of a low virulence
strain (Su) of Streptococcus pyogenes incubated with ben-
zylpenicillin, has been used in sclerotherapy for neck lym-
phangioma, malignant pleural effusion, and intractable
pneumothorax with satisfactory results.6971 No major
complication of pleurodesis using picibanil was reported.
The main side effects of the pleurodesis with picibanil were
fever and chest pain, which were well controlled by
nonsteroidal anti-inflammatory drugs.55,69
Iodopovidone
Iodopovidone is a topical antiseptic and has been shown to
be safe and effective in several studies.30,31,72 A solution
containing a mixture of 20-mL 10% iodopovidone and 80-mL
normal saline was used to create pleurodesis. Iodopovidone
pleurodesis is generally safe. The most common side effecteurodesis for spontaneous pneumothorax.
ct Side effects and complications
reased pneumothorax
urrence to 0e9%
Chest pain (7e15.6%), fever
(1.6e63.2%), dyspnea (57.9%),
pleural effusion (1.2%),
pneumonia (0.5e0.9%),
hemothorax (0.9%), and ARDS
(0e9%)
sing air leakage in
93%
reased pneumothorax
urrence to 0e29%
r VATS
Empyema (5e9.4%), pleural
effusion (5e15.6%), and fever
(10e12.5%)
reased pneumothorax
urrence to 9e25%
Chest pain (33e90%), fever
(9e81%), dyspnea (36%), and
elevated liver enzyme (45%)
sing air leakage in 63% Chest pain, fever (1%), and
loculated effusion (1.7%)
reased pneumothorax
urrence to 13e29%
Chest pain (67%)
reased pneumothorax
urrence to 2e4%
Chest pain (44.6e83.5%), fever
(4.1%), and hemothorax (0.6%)
reased pneumothorax
urrence to 0e6%
Chest pain (13%), fever
(6.1e33%), empyema, and wound
infection (2.4%)
sing air leakage in 95%
decreased
umothorax recurrence
% after VATS
Chest pain and fever (21%)
ous pneumothorax; SSPZ secondary spontaneous pneumothorax;
Chemical pleurodesis for pneumothorax 753is chest pain. Fever and empyema were also mentioned in
some studies with low incidence.72,73
Conclusions and future perspectives
Although there are many options in the management of
spontaneous pneumothorax, chemical pleurodesis should
play a more important role in this benign disease. The most
updated clinical trial showed that minocycline pleurodesis
effectively reduces pneumothorax recurrence and subse-
quent thoracoscopic surgery in the first episode of PSP. For
pneumothorax patients suffered from persistent air
leakage, pleurodesis using autologous blood patch, talc,
and picibanil are safe and effective. Additional chemical
pleurodesis following VATS bullectomy was also effective to
reduce the pneumothorax recurrence rate in PSP patients.
More and more clinical evidence showed that chemical
pleurodesis through a drainage tube/catheter is easy, safe,
and cost-effective for the treatment of spontaneous
pneumothorax. The optimal timing and choice of chemical
pleurodesis for spontaneous pneumothorax, however, de-
pends on the patient’s condition, physician’s experience,
and availability of sclerosants. The indications, effects, and
complications of common sclerosing agents are summarized
in Table 1.11,22,27e30,34,40,41,43e49,53,55,58e61,66e69,72e77
Future studies should focus on the comparison of safety
and efficacy of different sclerosing agents in specific clin-
ical settings of spontaneous pneumothorax.
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